Study on the Change of Fatigue in Gastrointestinal Cancer Patients With the Time Relapse After Chemotherapy.
- Author:
Jee Won PARK
1
;
Yong Soon KIM
;
Mi Sook SUE
Author Information
1. Division of Nursing Science, College of Medicine, Ajou University, Korea.
- Publication Type:Original Article
- Keywords:
Fatigue;
Cancer patients;
Chemotherapy
- MeSH:
Diagnosis;
Drug Therapy*;
Fatigue*;
Gastrointestinal Neoplasms*;
Gyeonggi-do;
Hematocrit;
Humans;
Induction Chemotherapy;
Occupations;
Piper;
Recurrence*
- From:Journal of Korean Academy of Adult Nursing
2001;13(4):620-631
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Fatigue is one of the most common complaints of cancer patients. In this study, we analyzed the change of fatigue level and general symptoms as time go by, so that, we could explain more on the mechanism and change of fatigue in relation with treatment, and explore the influencing factors. METHOD: The subjects of this study were 50 GI cancer patients who have visited the cancer center of A hospital in Suwon. We measured fatigue by using the Revised Piper Fatigue Scale(RPFS) at the time of starting and finishing induction chemotherapy, and starting the 2nd cycle of chemotherapy. RESULTS: 1) The fatigue score was 2.81, 3.73, and 3.82 in a 10 point scale at the time of starting and finishing induction chemotherapy, and starting the 2nd chemotherapy, respectively. This means fatigue persisted until after the treatment. 2) Fifty two percent of participants complained of some kinds of symptoms when starting the treatment, and the proportion increased up to 92% when finishing the treatment. 3) Fatigue scores were significantly high in patients with fatigue-related symptoms than for patients without those symptoms. 4) Fatigue scores showed significant differences according to patients' general characteristics such as age, educational level, economic status, occupation, diagnosis, hematocrit, weight, and amount of sleepy. CONCLUSION: We have to develop intervention strategies to reduce fatigue in cancer patients in the consideration of influencing factors.
